Life-Changing Medicines.
Redefining Possibilities.
Jazz Pipeline
PRE-CLINICAL
Oxybate
once-nightly dosing
CombiPlex
Solid tumors

CombiPlex

Asparaginase
Acute lymphocytic leukemia (ALL)/other hematological malignancies
Recombinant pegaspargase
hematological
malignancies
Defibrotide
Exploratory activities

Exosome NRAS
Hematologic malignancies§

Exosome STAT3
Hematologic malignancies§

Exosome candidates
Solid tumors/Hematologic malignancies§

PHASE 1
CPX-351 + gemtuzumab
R/R AML or HMA Failure
MDS*† (ages ≥18)

CPX-351 + venetoclax
Low intensity dosing for unfit AML†

IMGN779
R/R CD33 + Acute Myeloid Leukaemia (AML)

IMGN632
hematological malignancies

PHASE 2
Solriamfetol
EDS in Parkinson’s disease
Defibrotide
prevention of acute GvHD
Defibrotide
TA-TMA†
Defibrotide
CAR-T associated neurotoxicity†

CPX-351 + venetoclax
de novo or R/R AML**

CPX-351
MDS**†

CPX-351
R/R AML

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
idiopathic hypersomnia

Defibrotide
prevention of VOD

CPX-351
AML or HR-MDS (AML19)**‡

CPX-351
AML or HR-MDS (AML18)**‡

REGULATORY
Solriamfetol EU
EDS in OSA or narcolepsy
Solriamfetol U.S.
EDS in OSA and narcolepsy

Sleep
Hematology / Oncology
Opt-in Opportunity
*Jazz & MD Anderson Cancer Center Study
** Key Cooperative Group Study
Planned
Study Sponsor – Cardiff University
§Jazz & Codiak BioSciences alliance
Jazz & ImmunoGen alliance

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By transforming biopharmaceutical discoveries into novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.